Establishment Labs Holdings Inc.

Equities

ESTA

VGG312491084

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
52.57 USD +0.81% Intraday chart for Establishment Labs Holdings Inc. -0.89% +103.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Citigroup Raises Price Target on Establishment Labs to $60 From $49, Maintains Buy Rating MT
Establishment Labs Says US FDA Schedules Preapproval Inspection of Motiva Implants Facility MT
Mizuho Securities Raiset Price Target on Establishment Labs to $65 From $50, Keeps Buy Rating MT
TD Cowen Adjusts Establishment Labs Price Target to $60 From $50, Maintains Outperform Rating MT
Transcript : Establishment Labs Holdings Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM
Transcript : Establishment Labs Holdings Inc., Q4 2023 Earnings Call, Feb 28, 2024
Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024 CI
Establishment Labs Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (ESTA) ESTABLISHMENT LABS HOLDINGS Reports Q4 Revenue $31.6M, vs. Street Est of $31.6M MT
Establishment Labs Announces Amended Credit Facility with Oaktree CI
Establishment Labs Holdings Inc. announced that it has received $49.999102 million in funding CI
Transcript : Establishment Labs Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM
Establishment Labs Launches $50 Million Private Placement; Reports Q4, 2023 Preliminary Revenue; Shares Rise 7% MT
Establishment Labs Holdings Inc. announced that it expects to receive $50 million in funding CI
Establishment Labs Holdings Inc. Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander CI
B. Riley Lowers Establishment Labs Holdings' PT to $50 From $95 After Q3 Topline Miss, Notes Lower Multiple; Maintains Buy Rating MT
Establishment Labs Shares Plunge After Q3 Misses, 2023 Revenue Guidance Cut MT
Transcript : Establishment Labs Holdings Inc., Q3 2023 Earnings Call, Nov 07, 2023
Establishment Labs Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (ESTA) ESTABLISHMENT LABS HOLDINGS Posts Q3 Revenue $38.5M, vs. Street Est of $40.5M MT
Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023 CI
B. Riley Adjusts Establishment Labs Price Target to $95 From $107, Maintains Buy Rating MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Establishment Labs Secures FDA Clearance for Motiva Flora Tissue Expander MT
Establishment Labs Announces FDA Clearance of Motiva Flora Smoothsilk Tissue Expander CI
Chart Establishment Labs Holdings Inc.
More charts
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
52.57 USD
Average target price
59.29 USD
Spread / Average Target
+12.77%
Consensus
  1. Stock Market
  2. Equities
  3. ESTA Stock
  4. News Establishment Labs Holdings Inc.
  5. Establishment Labs : Goldman Sachs Adjusts Establishment Labs Holdings' Price Target to $78 from $68, Keeps Neutral Rating